Published in Cancer on March 01, 2007
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant (2009) 5.10
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer (2014) 1.93
Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer (2011) 1.78
Management of oral mucositis in patients who have cancer. Dent Clin North Am (2008) 1.72
Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection. Genome Med (2016) 1.47
Amelioration of Chemotherapy-Induced Intestinal Mucositis by Orally Administered Probiotics in a Mouse Model. PLoS One (2015) 1.41
Implementation of a hospital oral care protocol and recording of oral mucositis in children receiving cancer treatment : a retrospective and a prospective study. Support Care Cancer (2012) 1.40
Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer (2012) 1.27
Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines. Ann Oncol (2011) 1.26
Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist (2011) 1.22
Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients. Support Care Cancer (2012) 1.17
Systematic review of basic oral care for the management of oral mucositis in cancer patients. Support Care Cancer (2013) 1.16
A systematic review with meta-analysis of the effect of low-level laser therapy (LLLT) in cancer therapy-induced oral mucositis. Support Care Cancer (2011) 1.15
Nutritional screening and early treatment of malnutrition in cancer patients. J Cachexia Sarcopenia Muscle (2011) 1.05
A systematic review of orofacial pain in patients receiving cancer therapy. Support Care Cancer (2010) 1.05
Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. Radiat Oncol (2010) 1.05
Radiation damage and radioprotectants: new concepts in the era of molecular medicine. Br J Radiol (2012) 1.05
Systematic review of natural agents for the management of oral mucositis in cancer patients. Support Care Cancer (2013) 1.04
Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy. Support Care Cancer (2012) 1.03
Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients. Support Care Cancer (2013) 1.02
Efficacy of palifermin (keratinocyte growth factor-1) in the amelioration of oral mucositis. Core Evid (2010) 1.01
Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients. Support Care Cancer (2013) 1.00
Emerging evidence on the pathobiology of mucositis. Support Care Cancer (2013) 0.99
Radiation proctitis: current strategies in management. Gastroenterol Res Pract (2011) 0.97
Emerging evidence on the pathobiology of mucositis. Support Care Cancer (2013) 0.97
Oral mucositis in cancer treatment: Natural history, prevention and treatment. Mol Clin Oncol (2014) 0.96
Addition of epidermal growth factor improves the rate of sulfur mustard wound healing in an in vitro model. Eplasty (2008) 0.96
Systematic review of amifostine for the management of oral mucositis in cancer patients. Support Care Cancer (2012) 0.96
Anti-inflammatory cytokines: important immunoregulatory factors contributing to chemotherapy-induced gastrointestinal mucositis. Chemother Res Pract (2012) 0.95
Gastrointestinal radiation injury: prevention and treatment. World J Gastroenterol (2013) 0.94
Macrophage dectin-1 expression is controlled by leukotriene B4 via a GM-CSF/PU.1 axis. J Immunol (2012) 0.94
Professional oral health care reduces oral mucositis and febrile neutropenia in patients treated with allogeneic bone marrow transplantation. Support Care Cancer (2011) 0.93
Methodology for the MASCC/ISOO Mucositis Clinical Practice Guidelines Update. Support Care Cancer (2012) 0.93
A traditional Japanese medicine--Hangeshashinto (TJ-14)--alleviates chemoradiation-induced mucositis and improves rates of treatment completion. Support Care Cancer (2014) 0.93
Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases. Support Care Cancer (2013) 0.93
Cyclooxygenase-2 and vascular endothelial growth factor expression in 5-fluorouracil-induced oral mucositis in hamsters: evaluation of two low-intensity laser protocols. Support Care Cancer (2009) 0.92
Oral status of patients submitted to autologous hematopoietic stem cell transplantation. Support Care Cancer (2013) 0.91
Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK. Drugs (2015) 0.90
Prevention and treatment of oral mucositis in children with cancer. J Pediatr Pharmacol Ther (2012) 0.88
Targeted inhibition of IL-18 attenuates irinotecan-induced intestinal mucositis in mice. Br J Pharmacol (2014) 0.88
Double-blind, placebo-controlled, randomized phase II study of TJ-14 (hangeshashinto) for gastric cancer chemotherapy-induced oral mucositis. Cancer Chemother Pharmacol (2014) 0.88
Treatment of oral mucositis pain following radiation therapy for head-and-neck cancer using a bioadhesive barrier-forming lipid solution. Support Care Cancer (2014) 0.87
TLR signaling modulates side effects of anticancer therapy in the small intestine. J Immunol (2015) 0.86
Development of the MASCC/ISOO Clinical Practice Guidelines for Mucositis: considerations underlying the process. Support Care Cancer (2012) 0.85
Development and evaluation of evidence-informed clinical nursing protocols for remote assessment, triage and support of cancer treatment-induced symptoms. Nurs Res Pract (2013) 0.85
Irinotecan disrupts tight junction proteins within the gut : implications for chemotherapy-induced gut toxicity. Cancer Biol Ther (2013) 0.85
Effects of acid antisecretory drugs on mucus barrier of the rat against 5-fluorouracil-induced gastrointestinal mucositis. Scand J Gastroenterol (2008) 0.84
Oral mucositis in children suffering from acute lymphoblastic leukaemia. Contemp Oncol (Pozn) (2012) 0.84
Oral complications in hematopoietic stem cell recipients: the role of inflammation. Mediators Inflamm (2014) 0.84
Symptoms of the oral cavity and their association with local microbiological and clinical findings--a prospective survey in palliative care. Support Care Cancer (2011) 0.84
Systematic review of miscellaneous agents for the management of oral mucositis in cancer patients. Support Care Cancer (2013) 0.83
Pain in blood cancers. Indian J Palliat Care (2011) 0.83
Oral complications and management strategies for patients undergoing cancer therapy. ScientificWorldJournal (2014) 0.83
The MASCC/ISOO Mucositis Guidelines Update: introduction to the first set of articles. Support Care Cancer (2012) 0.83
Oral Mucositis Induced By Anticancer Therapies. Curr Oral Health Rep (2015) 0.83
The effect of polyvinylpyrrolidone-sodium hyaluronate gel (Gelclair) on oral microbial colonization and pain control compared with other rinsing solutions in patients with oral mucositis after allogeneic stem cells transplantation. Med Sci Monit (2011) 0.82
Effects of professional oral health care on reducing the risk of chemotherapy-induced oral mucositis. Support Care Cancer (2014) 0.82
Protein fraction of Calotropis procera latex protects against 5-fluorouracil-induced oral mucositis associated with downregulation of pivotal pro-inflammatory mediators. Naunyn Schmiedebergs Arch Pharmacol (2012) 0.82
Progress of oral care and reduction of oral mucositis--a pilot study in a hematopoietic stem cell transplantation ward. Support Care Cancer (2010) 0.82
Prevalence of clinically relevant oral mucositis in outpatients receiving myelosuppressive chemotherapy for solid tumors. Support Care Cancer (2011) 0.82
The impact of oral herpes simplex virus infection and candidiasis on chemotherapy-induced oral mucositis among patients with hematological malignancies. Eur J Clin Microbiol Infect Dis (2011) 0.82
Effect of low-level laser therapy on inflammatory mediator release during chemotherapy-induced oral mucositis: a randomized preliminary study. Lasers Med Sci (2014) 0.82
Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis. Cancer Chemother Pharmacol (2015) 0.81
Efficacy of CR3294, a new benzamidine derivative, in the prevention of 5-fluorouracil-induced gastrointestinal mucositis and diarrhea in mice. Cancer Chemother Pharmacol (2009) 0.81
Prospective evaluation of incidence and severity of oral mucositis induced by conventional chemotherapy in solid tumors and malignant lymphomas. Support Care Cancer (2011) 0.81
Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors. EJC Suppl (2013) 0.81
Factors associated with weight loss during radiotherapy in patients with stage I or II head and neck cancer. Support Care Cancer (2011) 0.81
Appropriate and necessary oral care for people with cancer: guidance to obtain the right oral and dental care at the right time. Support Care Cancer (2014) 0.80
Herbal substance, acteoside, alleviates intestinal mucositis in mice. Gastroenterol Res Pract (2015) 0.80
L-glutamine decreases the severity of mucositis induced by chemoradiotherapy in patients with locally advanced head and neck cancer: a double-blind, randomized, placebo-controlled trial. Oncol Rep (2014) 0.80
Double-blind, randomized pilot study of bioadhesive chlorhexidine gel in the prevention and treatment of mucositis induced by chemoradiotherapy of head and neck cancer. Med Oral Patol Oral Cir Bucal (2015) 0.80
Effect of tumour-cell-derived or recombinant keratinocyte growth factor (KGF) on proliferation and radioresponse of human epithelial tumour cells (HNSCC) and normal keratinocytes in vitro. Radiat Environ Biophys (2010) 0.80
Oral health in children with leukemia. Indian J Palliat Care (2012) 0.80
Healing action of topical chamomile on 5-fluoracil induced oral mucositis in hamster. Support Care Cancer (2010) 0.80
A randomized placebo-controlled trial of manuka honey for radiation-induced oral mucositis. Support Care Cancer (2013) 0.79
An oral history of MASCC, its origin and development from MASCC's beginnings to 2009. Support Care Cancer (2010) 0.79
Dark Agouti rat model of chemotherapy-induced mucositis: establishment and current state of the art. Exp Biol Med (Maywood) (2015) 0.79
The Adaptor Protein Myd88 Is a Key Signaling Molecule in the Pathogenesis of Irinotecan-Induced Intestinal Mucositis. PLoS One (2015) 0.79
Oral Mucositis: understanding the pathology and management. Hippokratia (2012) 0.79
Treating oral mucositis with a supersaturated calcium phosphate rinse: comparison with control in patients undergoing allogeneic hematopoietic stem cell transplantation. Support Care Cancer (2012) 0.79
Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. Support Care Cancer (2013) 0.79
Preventive effects of amino-acid-rich elemental diet Elental(®) on chemotherapy-induced oral mucositis in patients with colorectal cancer: a prospective pilot study. Support Care Cancer (2015) 0.78
Prevention and management of mucositis in patients with cancer: a review article. Iran J Cancer Prev (2012) 0.78
Microbiology and epidemiology of oral yeast colonization in hemopoietic progenitor cell transplant recipients. Oral Surg Oral Med Oral Pathol Oral Radiol (2013) 0.78
A survey of chinese medicinal herbal treatment for chemotherapy-induced oral mucositis. Evid Based Complement Alternat Med (2013) 0.78
Pharmacotherapy for adverse events reduces the length of hospital stay in patients admitted to otolaryngology ward: a single arm intervention study. PLoS One (2014) 0.78
N08C9 (Alliance): A Phase 3 Randomized Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy. Int J Radiat Oncol Biol Phys (2016) 0.78
Supportive cryotherapy: a review from head to toe. J Pain Symptom Manage (2013) 0.77
"Coffee plus honey" versus "topical steroid" in the treatment of chemotherapy-induced oral mucositis: a randomised controlled trial. BMC Complement Altern Med (2014) 0.77
The effect of a supersaturated calcium phosphate mouth rinse on the development of oral mucositis in head and neck cancer patients treated with (chemo)radiation: a single-center, randomized, prospective study of a calcium phosphate mouth rinse + standard of care versus standard of care. Support Care Cancer (2013) 0.77
Complementary strategies for the management of radiation therapy side effects. J Adv Pract Oncol (2013) 0.77
γ-Tocotrienol prevents 5-FU-induced reactive oxygen species production in human oral keratinocytes through the stabilization of 5-FU-induced activation of Nrf2. Int J Oncol (2015) 0.77
Continuous enteral administration can overcome the limited capacity to absorb glucose in rats with methotrexate-induced gastrointestinal mucositis. Support Care Cancer (2012) 0.77
Sodium glucose cotransporter 1 ligand BLF501 as a novel tool for management of gastrointestinal mucositis. Mol Cancer (2014) 0.77
New pathways for alimentary mucositis. J Oncol (2008) 0.77
Oral and dental considerations in pediatric leukemic patient. ISRN Hematol (2014) 0.77
Efficacy of elemental diet on prevention for chemoradiotherapy-induced oral mucositis in patients with oral squamous cell carcinoma. Support Care Cancer (2015) 0.77
Morphine mouthwash for the management of oral mucositis in patients with head and neck cancer. Adv Biomed Res (2015) 0.76
Human uridine phosphorylase-1 inhibitors: a new approach to ameliorate 5-fluorouracil-induced intestinal mucositis. Invest New Drugs (2014) 0.76
Irinotecan-induced alterations in intestinal cell kinetics and extracellular matrix component expression in the Dark Agouti rat. Int J Exp Pathol (2011) 0.76
Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer (2004) 3.83
Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc (2011) 3.76
Adjunctive techniques for oral cancer examination and lesion diagnosis: a systematic review of the literature. J Am Dent Assoc (2008) 3.74
Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol (2003) 3.46
Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study. J Clin Oncol (2009) 2.64
Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol (2006) 2.52
Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant (2006) 2.44
A systematic review of dental disease in patients undergoing cancer therapy. Support Care Cancer (2010) 2.43
Oral lichen planus and oral lichenoid lesions: diagnostic and therapeutic considerations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2007) 2.40
Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc (2008) 2.36
Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer (2004) 2.29
The connection between human papillomavirus and oropharyngeal squamous cell carcinomas in the United States: implications for dentistry. J Am Dent Assoc (2011) 2.10
Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer (2005) 1.94
Systematic reviews and guidelines for oral complications of cancer therapies: current challenges and future opportunities. Support Care Cancer (2010) 1.93
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer (2014) 1.93
Symptom clusters: concept analysis and clinical implications for cancer nursing. Cancer Nurs (2005) 1.86
Clinical management of salivary gland hypofunction and xerostomia in head-and-neck cancer patients: successes and barriers. Int J Radiat Oncol Biol Phys (2010) 1.84
Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract (2006) 1.84
Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol (2003) 1.80
Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer (2011) 1.78
Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology (2006) 1.72
Management of oral mucositis in patients who have cancer. Dent Clin North Am (2008) 1.72
A systematic review of bisphosphonate osteonecrosis (BON) in cancer. Support Care Cancer (2010) 1.68
Body mass index and outcomes in patients receiving chemotherapy for intermediate-grade B-cell non-Hodgkin lymphoma. Leuk Lymphoma (2010) 1.61
Microarrays and clinical dentistry. J Am Dent Assoc (2003) 1.53
Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis: oral mucositis patient provider advisory board. Cancer Invest (2002) 1.49
The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev (2007) 1.47
Osteoporosis and its implications for dental patients. J Am Dent Assoc (2008) 1.45
Toluidine blue staining identifies high-risk primary oral premalignant lesions with poor outcome. Cancer Res (2005) 1.44
Radiographic and clinical features of temporomandibular dysfunction in patients following indirect trauma: a retrospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2007) 1.42
Burning mouth syndrome. Am Fam Physician (2002) 1.40
Does Medicare coverage of colonoscopy reduce racial/ethnic disparities in cancer screening among the elderly? Health Aff (Millwood) (2006) 1.39
Exposed bone in the palate. J Am Dent Assoc (2007) 1.37
Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol (2007) 1.35
A systematic review of oral fungal infections in patients receiving cancer therapy. Support Care Cancer (2010) 1.32
Bleeding disorders of importance in dental care and related patient management. J Can Dent Assoc (2007) 1.32
Disparities in colorectal screening between US-born and foreign-born populations: evidence from the 2000 National Health Interview Survey. J Cancer Educ (2008) 1.32
Management of dental patients taking common hemostasis-altering medications. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2007) 1.31
Proliferative verrucous leukoplakia and its progression to oral carcinoma: a review of the literature. J Oral Pathol Med (2007) 1.26
A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation. Support Care Cancer (2007) 1.25
Bardoxolone methyl analogs RTA 405 and dh404 are well tolerated and exhibit efficacy in rodent models of Type 2 diabetes and obesity. Am J Physiol Renal Physiol (2013) 1.25
A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer (2010) 1.25
Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapy. J Pain Symptom Manage (2009) 1.25
Oral and dental management related to radiation therapy for head and neck cancer. J Can Dent Assoc (2003) 1.23
Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res (2008) 1.23
A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2005) 1.23
Systematic review of laser and other light therapy for the management of oral mucositis in cancer patients. Support Care Cancer (2012) 1.23
Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol (2003) 1.22
Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist (2011) 1.22
Carcinoma of the tongue: a case series analysis of clinical presentation, risk factors, staging, and outcome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2004) 1.22
Burning mouth syndrome: recognition, understanding, and management. Oral Maxillofac Surg Clin North Am (2008) 1.22
Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer (2007) 1.18
Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients. Support Care Cancer (2012) 1.17
Epidemiology and outcomes of serious influenza-related infections in the cancer population. Cancer (2005) 1.17
Intraoral melanoma: long-term follow-up and implication for dental clinicians. A case report and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2003) 1.17
Oral cancer: current and future diagnostic techniques. Am J Dent (2008) 1.16
Swallowing dysfunction in cancer patients. Support Care Cancer (2011) 1.12
Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review. Nat Rev Endocrinol (2010) 1.12
Management of oral epithelial dysplasia: a review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2007) 1.12
Interobserver reliability in the histopathologic diagnosis of oral pre-malignant and malignant lesions. J Oral Pathol Med (2004) 1.12
Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol (2008) 1.12
Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. Support Care Cancer (2013) 1.10
Refining physician quality indicators for screening mammography in older women: distinguishing appropriate use from overuse. J Am Geriatr Soc (2013) 1.09
Concern The cost burden of oral, oral pharyngeal, and salivary gland cancers in three groups: commercial insurance, Medicare, and Medicaid. Head Neck Oncol (2012) 1.09
Osteoradionecrosis in cancer patients: the evidence base for treatment-dependent frequency, current management strategies, and future studies. Support Care Cancer (2010) 1.09
Influence of family history and preventive health behaviors on colorectal cancer screening in African Americans. Cancer (2008) 1.08
Hyposalivation in elderly patients. J Can Dent Assoc (2006) 1.08
A systematic review of trismus induced by cancer therapies in head and neck cancer patients. Support Care Cancer (2010) 1.07
Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol (2006) 1.07
Factors influencing the volume-outcome relationship in gastrectomies: a population-based study. Ann Surg Oncol (2007) 1.06
Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther (2008) 1.05
A systematic review of orofacial pain in patients receiving cancer therapy. Support Care Cancer (2010) 1.05
Advances in hematologic stem cell transplant: an update for oral health care providers. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2009) 1.05
Antimicrobial therapy to prevent or treat oral mucositis. Lancet Infect Dis (2003) 1.04
Nasopharyngeal carcinoma: current management, future directions and dental implications. Oral Oncol (2007) 1.04
Salen Mn complexes mitigate radiation injury in normal tissues. Anticancer Agents Med Chem (2011) 1.03
Complications of radiation therapy for head and neck cancers. The patient's perspective. Cancer Nurs (2002) 1.03
Treatment of mucositis, including new medications. Cancer J (2006) 1.03
Evidence that TRPC1 contributes to calcium-induced differentiation of human keratinocytes. Pflugers Arch (2005) 1.02
Burning mouth syndrome and other oral sensory disorders: a unifying hypothesis. Pain Res Manag (2003) 1.02
Assessing oral cancer early detection: clarifying dentists' practices. J Public Health Dent (2010) 1.01
Anxiety, depression, and pain: differences by primary cancer. Support Care Cancer (2009) 1.01
Role of the cyclooxygenase pathway in chemotherapy-induced oral mucositis: a pilot study. Support Care Cancer (2009) 1.01